Facebook
Twitter
LinkedIn
ForwardRyan Cassaday, MD
Dr. Cassaday completed his undergraduate and medical training at the University of Wisconsin in Madison. In 2010, he started Hematology/Oncology fellowship at the University of Washington and Fred Hutchinson Cancer Research Center. He then joined the faculty at these institutions in 2014, with a focus on acute lymphoblastic leukemia in adults. Since then, he has led several investigator-initiated and industry-sponsored clinical trials of various strategies for this disease, including novel agents and cellular therapies. He has a particular interest in developing novel chemotherapy strategies for high-risk populations, including older adults and those with relapsed/refractory disease. He has served on the National Comprehensive Cancer Network Guidelines Panel for Acute Lymphoblastic Leukemia and the Leukemia Working Group of the Southwest Oncology Group.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AmgenTopic:B-cell ALLDate added:05/30/2023Date updated:05/30/2024Relationship end date:08/01/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:KiteTopic:B-cell ALLDate added:05/30/2023Date updated:05/30/2024Relationship end date:05/15/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:PfizerTopic:B-cell ALLDate added:05/30/2023Date updated:05/30/2024Relationship end date:05/31/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:ServierTopic:B-cell ALLDate added:05/30/2023Date updated:05/30/2024Relationship end date:12/31/2025
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:IncyteTopic:B-cell ALLDate added:05/30/2023Date updated:05/30/2024Relationship end date:01/30/2026
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:VandaTopic:Hematologic MalignancyDate added:05/30/2023Date updated:05/30/2024Relationship end date:04/30/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:JazzTopic:Advisor: B-cell ALLDate added:05/30/2023Date updated:05/30/2024Relationship end date:06/19/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:KiteTopic:Advisor: B-cell ALLDate added:05/30/2023Date updated:05/30/2024Relationship end date:12/10/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:PfizerTopic:Advisor: B-cell ALLDate added:05/30/2023Date updated:05/30/2024Relationship end date:04/12/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:AutolusTopic:Independent Response Review CommitteeDate added:05/30/2023Date updated:05/30/2024Relationship end date:12/02/2024